Why argenx SE (ARGX) Stock Is Up Today

argenx SE (ARGX) is up 5.5% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to argenx’s July 23, 2026 half-year update, which showed another strong quarter for VYVGART and improving profitability. Investors also seem to be responding to the broader U.S. launch into all adult generalized myasthenia gravis serotypes and the company’s reaffirmed late-2026 pipeline readouts.

Details:

Second-quarter 2026 global product net sales reached $1.516 billion, up 60% from the prior year and 17% from the prior quarter.

Operating profit rose to $494 million in the quarter, versus $201 million a year earlier, while cash, cash equivalents, and current financial assets totaled $5.2 billion at June 30, 2026.

During the quarter, argenx launched the expanded U.S. label for VYVGART and VYVGART Hytrulo to cover all adult gMG serotypes, widening the eligible patient pool.

The company also said key registrational readouts remain on track, including autoimmune myositis in the third quarter of 2026 and MMN for empasiprubart in the fourth quarter of 2026.

Sources:

argenx, MarketScreener

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive ARGX Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$ARGX Hedge Fund Activity

We have seen 211 institutional investors add shares of $ARGX stock to their portfolio, and 242 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC removed 601,285 shares (-10.8%) from their portfolio in Q1 2026, for an estimated $439,088,371
WELLINGTON MANAGEMENT GROUP LLP added 342,221 shares (+50.4%) to their portfolio in Q1 2026, for an estimated $249,906,885
CAPITAL WORLD INVESTORS added 339,982 shares (+17.7%) to their portfolio in Q1 2026, for an estimated $248,271,855
ARTISAN PARTNERS LIMITED PARTNERSHIP removed 288,960 shares (-16.4%) from their portfolio in Q1 2026, for an estimated $211,013,040
CLEARBRIDGE INVESTMENTS, LLC removed 282,408 shares (-55.0%) from their portfolio in Q1 2026, for an estimated $206,228,442
CORIENT PRIVATE WEALTH LLC removed 244,317 shares (-99.1%) from their portfolio in Q1 2026, for an estimated $178,412,489
VOYA INVESTMENT MANAGEMENT LLC removed 163,553 shares (-96.7%) from their portfolio in Q1 2026, for an estimated $119,434,578

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ARGX Congressional Stock Trading

Members of Congress have traded $ARGX stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $ARGX stock by members of Congress over the last 6 months:

SENATOR ALAN ARMSTRONG purchased up to $15,000 on 03/30.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$ARGX Price Targets

Multiple analysts have issued price targets for $ARGX recently. We have seen 11 analysts offer price targets for $ARGX in the last 6 months, with a median target of $1014.0.

Here are some recent targets:

Luca Issi from RBC Capital set a target price of $945.0 on 07/07/2026
Tazeen Ahmad from B of A Securities set a target price of $1088.0 on 07/02/2026
Douglas Tsao from HC Wainwright & Co. set a target price of $940.0 on 06/25/2026
Matthew Harrison from Morgan Stanley set a target price of $1180.0 on 06/24/2026
David Nierengarten from Wedbush set a target price of $1000.0 on 06/11/2026
Derek Archila from Wells Fargo set a target price of $1291.0 on 06/01/2026
Gavin Clark-Gartner from Evercore ISI Group set a target price of $1059.0 on 05/15/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.